Cairo, Berlin – August
4, 2024 - Minapharm, the leading pharmaceutical
and biopharmaceutical company in Egypt, Africa, and the Middle East announced
on August 4th, the appointment of Prof. Ralf Wagner to the Supervisory Board of
its Berlin-based subsidiary ProBioGen AG, a world leading Contract Development
and Manufacturing Organization (CDMO) and technology provider with expertise in
cell line engineering, process development, and GMP manufacturing.
Prof. Wagner is a renowned expert in
the field of Molecular Microbiology and Virology, with over 20 years of
experience excelling in both his academic and strategic organizational leadership
roles.
He carries the role of Head of
Molecular Microbiology and Virology at University of Regensburg, Germany, and
is a distinguished expert in vaccine research and development, and a reviewer
and advisor of various prestigious scientific journals such as Nature, PNAS, and
more. He was also amongst the first scientists to recognize the value of gene
design and synthesis for different areas of biotechnology such as metabolic
engineering, vaccine design, translating basic research tools into scalable
technologies.
Dr. Wagner’s organizational expertise encompasses
many strategic leadership positions in European and US biotech companies
serving as the Founder, Co-CEO and CSO of
GeneArt AG, one of
the foremost global specialists in the area of Synthetic Biology with a
portfolio ranging from synthetic genes production to plasmid DNA production, and
the Vice President R&D Synthetic Biology, Site and Integration Lead of Life
technologies. His contributions have been recognized by numerous
international awards, including the European Biotech Award and Bavaria's Fast
50.
Dr. Wafik Bardissi, Chair of the
Supervisory Board of ProBioGen AG and CEO and Chair of the parent company
Minapharm commented: “We welcome Prof. Ralf Wagner. With his distinguished
background in scientific research and impressive track record in biotech
entrepreneurship, he brings invaluable expertise and visionary leadership to
ProBioGen’s supervisory board, instrumental in driving our mission to further
expand the company’s CDMO business including its cutting-edge gene-based
proprietary technologies. “
About Minapharm
Pharmaceuticals
Minapharm Pharmaceuticals is a leading
pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical
company in Africa with over 20 years of experience in cellular and bioprocess
engineering. Headquartered in Cairo, Minapharm commercializes over 100
life-saving and life-enhancing products ranging from small molecules to complex
genetically engineered proteins, with an impressive immunotherapy pipeline.
Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG, a
globally renowned CDMO and provider of innovative proprietary technologies in
the fields of monoclonal antibodies, protein, viral, and cell therapies to the
global biotech industry at large, Minapharm has established an integrated
business model making it to date the only gene-to-market biopharmaceutical
company in the region. Minapharm employs a collective workforce of over 2,000
and is listed on the Cairo and Alexandria stock exchanges (Symbol: MIPH).
About ProBioGen AG
ProBioGen is a premiere, Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and GMP-compliant manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen has been operational for almost 30 years. At four locations in Berlin, 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.